Roche Tasmar anti-Parkinson's therapy reduces "off" time 20%-30%, U.K. labeling states.
Executive Summary
ROCHE TASMAR REDUCES PARKINSON's "OFF" TIME 20%-30%, U.K. labeling for the therapy states. Tasmar (tolcapone) was approved by the European Medicine Evaluation Agency Aug. 27 as an adjunct to levodopa/carbidopa treatment and has become available in Germany and the U.K., Roche announced. Tasmar is the first catechol-O-methyltransferase inhibitor to come to market and will soon be available in other European countries, the company stated.